A citation-based method for searching scientific literature

K Metcalfe, S Gershman, H T Lynch, P Ghadirian, N Tung, C Kim-Sing, O I Olopade, S Domchek, J McLennan, A Eisen, W D Foulkes, B Rosen, P Sun, S A Narod. Br J Cancer 2011
Times Cited: 120







List of co-cited articles
746 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Kelly Metcalfe, Henry T Lynch, Parviz Ghadirian, Nadine Tung, Ivo Olivotto, Ellen Warner, Olufunmilayo I Olopade, Andrea Eisen, Barbara Weber, Jane McLennan,[...]. J Clin Oncol 2004
420
35

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Monika K Graeser, Christoph Engel, Kerstin Rhiem, Dorothea Gadzicki, Ulrich Bick, Karin Kast, Ursula G Froster, Bettina Schlehe, Astrid Bechtold, Norbert Arnold,[...]. J Clin Oncol 2009
190
31

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
30

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
498
30

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
849
29

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
27

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
867
25

Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
Lori J Pierce, Albert M Levin, Timothy R Rebbeck, Merav A Ben-David, Eitan Friedman, Lawrence J Solin, Eleanor E Harris, David K Gaffney, Bruce G Haffty, Laura A Dawson,[...]. J Clin Oncol 2006
204
23

Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
Kathleen E Malone, Colin B Begg, Robert W Haile, Ake Borg, Patrick Concannon, Lina Tellhed, Shanyan Xue, Sharon Teraoka, Leslie Bernstein, Marinela Capanu,[...]. J Clin Oncol 2010
111
19

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
C T M Brekelmans, M M A Tilanus-Linthorst, C Seynaeve, A vd Ouweland, M B E Menke-Pluymers, C C M Bartels, M Kriege, A N van Geel, C W Burger, A M M Eggermont,[...]. Eur J Cancer 2007
146
19

Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.
Kelly Metcalfe, Shelley Gershman, Parviz Ghadirian, Henry T Lynch, Carrie Snyder, Nadine Tung, Charmaine Kim-Sing, Andrea Eisen, William D Foulkes, Barry Rosen,[...]. BMJ 2014
158
19


Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
18

Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Lori J Pierce, Kelly-Anne Phillips, Kent A Griffith, Saundra Buys, David K Gaffney, Meena S Moran, Bruce G Haffty, Merav Ben-David, Bella Kaufman, Judy E Garber,[...]. Breast Cancer Res Treat 2010
101
17

Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Kelly Metcalfe, Henry T Lynch, Parviz Ghadirian, Nadine Tung, Charmaine Kim-Sing, Olufunmilayo I Olopade, Susan Domchek, Andrea Eisen, William D Foulkes, Barry Rosen,[...]. Breast Cancer Res Treat 2011
42
40

Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.
Bruce G Haffty, Elizabeth Harrold, Atif J Khan, Pradip Pathare, Tanya E Smith, Bruce C Turner, Peter M Glazer, Barbara Ward, Daryl Carter, Ellen Matloff,[...]. Lancet 2002
195
16

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Kelly-Anne Phillips, Roger L Milne, Matti A Rookus, Mary B Daly, Antonis C Antoniou, Susan Peock, Debra Frost, Douglas F Easton, Steve Ellis, Michael L Friedlander,[...]. J Clin Oncol 2013
109
16

Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.
D Gareth R Evans, Sarah L Ingham, Andrew Baildam, Gary L Ross, Fiona Lalloo, Iain Buchan, Anthony Howell. Breast Cancer Res Treat 2013
93
16

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.
T C van Sprundel, M K Schmidt, M A Rookus, R Brohet, C J van Asperen, E J Th Rutgers, L J Van't Veer, R A E M Tollenaar. Br J Cancer 2005
178
15


Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
14

Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Anne S Reiner, Esther M John, Jennifer D Brooks, Charles F Lynch, Leslie Bernstein, Lene Mellemkjær, Kathleen E Malone, Julia A Knight, Marinela Capanu, Sharon N Teraoka,[...]. J Clin Oncol 2013
73
19

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.
Kerstin Rhiem, Christoph Engel, Monika Graeser, Silke Zachariae, Karin Kast, Marion Kiechle, Nina Ditsch, Wolfgang Janni, Christoph Mundhenke, Michael Golatta,[...]. Breast Cancer Res 2012
58
24

Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.
Bernadette A M Heemskerk-Gerritsen, Matti A Rookus, Cora M Aalfs, Margreet G E M Ausems, Johanna M Collée, Liesbeth Jansen, C Marleen Kets, Kristien B M I Keymeulen, Linetta B Koppert, Hanne E J Meijers-Heijboer,[...]. Int J Cancer 2015
85
16

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
Dorina M van der Kolk, Geertruida H de Bock, Beike K Leegte, Michael Schaapveld, Marian J E Mourits, Jakob de Vries, Annemieke H van der Hout, Jan C Oosterwijk. Breast Cancer Res Treat 2010
116
13

Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment.
Todd M Tuttle, Elizabeth B Habermann, Erin H Grund, Todd J Morris, Beth A Virnig. J Clin Oncol 2007
459
13

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman,[...]. Cancer Epidemiol Biomarkers Prev 2012
328
13

Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?
Carlos A Garcia-Etienne, Monica Barile, Oreste D Gentilini, Edoardo Botteri, Nicole Rotmensz, Andrea Sagona, Gabriel Farante, Viviana Galimberti, Alberto Luini, Paolo Veronesi,[...]. Ann Surg Oncol 2009
56
21

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Mark E Robson, Pierre O Chappuis, Jaya Satagopan, Nora Wong, Jeff Boyd, John R Goffin, Clifford Hudis, David Roberge, Larry Norton, Louis R Bégin,[...]. Breast Cancer Res 2004
210
12

Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Jonine L Bernstein, Duncan C Thomas, Roy E Shore, Mark Robson, John D Boice, Marilyn Stovall, Michael Andersson, Leslie Bernstein, Kathleen E Malone, Anne S Reiner,[...]. Eur J Cancer 2013
43
27

Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Youlia M Kirova, Dominique Stoppa-Lyonnet, Alexia Savignoni, Brigitte Sigal-Zafrani, Nicolas Fabre, Alain Fourquet. Eur J Cancer 2005
90
12

Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Kelly A Metcalfe, Jan Lubinski, Parviz Ghadirian, Henry Lynch, Charmaine Kim-Sing, Eitan Friedman, William D Foulkes, Susan Domchek, Peter Ainsworth, Claudine Isaacs,[...]. J Clin Oncol 2008
120
11

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Kerryn W Reding, Jonine L Bernstein, Bryan M Langholz, Leslie Bernstein, Robert W Haile, Colin B Begg, Charles F Lynch, Patrick Concannon, Ake Borg, Sharon N Teraoka,[...]. Breast Cancer Res Treat 2010
39
28

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
Amy P M Finch, Jan Lubinski, Pål Møller, Christian F Singer, Beth Karlan, Leigha Senter, Barry Rosen, Lovise Maehle, Parviz Ghadirian, Cezary Cybulski,[...]. J Clin Oncol 2014
342
11

Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.
Antonis Valachis, Andreas D Nearchou, Pehr Lind. Breast Cancer Res Treat 2014
67
16

Variation of breast cancer risk among BRCA1/2 carriers.
Colin B Begg, Robert W Haile, Ake Borg, Kathleen E Malone, Patrick Concannon, Duncan C Thomas, Bryan Langholz, Leslie Bernstein, Jørgen H Olsen, Charles F Lynch,[...]. JAMA 2008
203
10

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Noah D Kauff, Susan M Domchek, Tara M Friebel, Mark E Robson, Johanna Lee, Judy E Garber, Claudine Isaacs, D Gareth Evans, Henry Lynch, Rosalind A Eeles,[...]. J Clin Oncol 2008
359
10

Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
D Ford, D F Easton, D T Bishop, S A Narod, D E Goldgar. Lancet 1994
10


Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
Jacek Gronwald, Nadine Tung, William D Foulkes, Kenneth Offit, Ruth Gershoni, Mary Daly, Charmaine Kim-Sing, Hakan Olsson, Peter Ainsworth, Andrea Eisen,[...]. Int J Cancer 2006
177
10

Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.
Tari A King, Rita Sakr, Sujata Patil, Inga Gurevich, Michelle Stempel, Michelle Sampson, Monica Morrow. J Clin Oncol 2011
231
10

Prophylactic mastectomy for the prevention of breast cancer.
Liz Lostumbo, Nora E Carbine, Judi Wallace. Cochrane Database Syst Rev 2010
196
10

Pathology of hereditary breast cancer.
Leonard Da Silva, Sunil R Lakhani. Mod Pathol 2010
54
18

Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer.
L C Verhoog, C T Brekelmans, C Seynaeve, E J Meijers-Heijboer, J G Klijn. Br J Cancer 2000
88
10

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
H Meijers-Heijboer, B van Geel, W L van Putten, S C Henzen-Logmans, C Seynaeve, M B Menke-Pluymers, C C Bartels, L C Verhoog, A M van den Ouweland, M F Niermeijer,[...]. N Engl J Med 2001
632
9

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Kelly A Metcalfe, Daphna Birenbaum-Carmeli, Jan Lubinski, Jacek Gronwald, Henry Lynch, Pal Moller, Parviz Ghadirian, William D Foulkes, Jan Klijn, Eitan Friedman,[...]. Int J Cancer 2008
246
9

Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
M Robson, D Levin, M Federici, J Satagopan, F Bogolminy, A Heerdt, P Borgen, B McCormick, C Hudis, L Norton,[...]. J Natl Cancer Inst 1999
123
9

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
S A Narod, J S Brunet, P Ghadirian, M Robson, K Heimdal, S L Neuhausen, D Stoppa-Lyonnet, C Lerman, B Pasini, P de los Rios,[...]. Lancet 2000
385
9

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Jacek Gronwald, Andre Robidoux, Charmaine Kim-Sing, Nadine Tung, Henry T Lynch, William D Foulkes, Siranoush Manoukian, Peter Ainsworth, Susan L Neuhausen, Rochelle Demsky,[...]. Breast Cancer Res Treat 2014
21
42

Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
Alexandra J van den Broek, Laura J van 't Veer, Maartje J Hooning, Sten Cornelissen, Annegien Broeks, Emiel J Rutgers, Vincent T H B M Smit, Cees J Cornelisse, Mike van Beek, Maryska L Janssen-Heijnen,[...]. J Clin Oncol 2016
53
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.